Abstract
The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that forms a multisubunit complex with numerous protein partners and it regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. A central role for mTOR in regulating T cell homeostasis is emerging. In various autoimmune diseases abnormal functioning, differentiation and/or activation of T cells have been documented and recent studies have detailed anomalous activation of various signaling axes including the mTOR pathway in these cells. In this review we summarize recent studies on the involvement of mTOR in T cell differentiation and metabolism, supporting a key role for this molecule in providing a direct link between these two processes. We also describe how the mTOR pathway affects multiple molecular processes in autoimmune diseases and discuss the potential of targeting this pathway in these disorders.
Keywords: mTOR, T lymphocytes, metabolism, autophagy, autoimmune diseases, mTOR inhibitors, rapamycin, vitamin D, Systemic lupus erythematosus (SLE), cytokines
Current Pharmaceutical Design
Title: mTOR Signaling and Metabolic Regulation of T Cells: New Potential Therapeutic Targets in Autoimmune Diseases
Volume: 17 Issue: 35
Author(s): Marina Pierdominici, Davide Vacirca, Federica Delunardo and Elena Ortona
Affiliation:
Keywords: mTOR, T lymphocytes, metabolism, autophagy, autoimmune diseases, mTOR inhibitors, rapamycin, vitamin D, Systemic lupus erythematosus (SLE), cytokines
Abstract: The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase that forms a multisubunit complex with numerous protein partners and it regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. A central role for mTOR in regulating T cell homeostasis is emerging. In various autoimmune diseases abnormal functioning, differentiation and/or activation of T cells have been documented and recent studies have detailed anomalous activation of various signaling axes including the mTOR pathway in these cells. In this review we summarize recent studies on the involvement of mTOR in T cell differentiation and metabolism, supporting a key role for this molecule in providing a direct link between these two processes. We also describe how the mTOR pathway affects multiple molecular processes in autoimmune diseases and discuss the potential of targeting this pathway in these disorders.
Export Options
About this article
Cite this article as:
Pierdominici Marina, Vacirca Davide, Delunardo Federica and Ortona Elena, mTOR Signaling and Metabolic Regulation of T Cells: New Potential Therapeutic Targets in Autoimmune Diseases, Current Pharmaceutical Design 2011; 17 (35) . https://dx.doi.org/10.2174/138161211798357809
DOI https://dx.doi.org/10.2174/138161211798357809 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Rationale for Comparative Studies of Accelerated Atherosclerosis in Rheumatic Diseases
Current Vascular Pharmacology PROGRAMMED Cell Clearance: Molecular Mechanisms and Role in Autoimmune Disease, Chronic Inflammation, and Anti-Cancer Immune Responses
Current Immunology Reviews (Discontinued) The Role of Infections in the Pathogenesis of Autoimmune Diseases
Current Drug Targets - Inflammation & Allergy Blood Brain Barrier Compromise with Endothelial Inflammation may Lead to Autoimmune Loss of Myelin during Multiple Sclerosis
Current Neurovascular Research Deaza Analogs of Folic Acid as Antitumor Agents
Current Pharmaceutical Design The AKT Axis as a Therapeutic Target in Autoimmune Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets CD24 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: Targeting Redundancy for Immunotherapy?
Current Immunology Reviews (Discontinued) Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Is Autoimmunity a Component of Natural Immunity to HIV?
Current HIV Research Mechanisms of Neutrophil-mediated Disease: Innovative Therapeutic Interventions
Current Pharmaceutical Design TNF, Cell Death and Inflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Characterization of Regulatory T-Cells in Multiple Sclerosis Patients Treated with Interferon Beta-1a
CNS & Neurological Disorders - Drug Targets Animal Models of Lupus and Lupus Nephritis
Current Pharmaceutical Design Protein Engineering Studies for C-C Chemokine Receptor Type 2 (CCR2)
Current Enzyme Inhibition Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design